Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $12.00 | Buy → Neutral | BofA Securities |
| 12/21/2022 | $26.00 | Buy | H.C. Wainwright |
– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program optimized based on encouraging results from early cohort – – Strengthened leadership team with addition of Paul Streck, MD, MBA, as head of R&D – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024. "We are pleased with the progress we have made across our pipeline and organiza
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference (Boston, MA) Monday, November 11, 2024 at 1:00 p.m. ET, Fireside Chat Stifel 2024 Healthcare Conference (New York, NY) Tuesday, November 19, 2024 at 11:30 a.m. ET, Fireside Chat A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the P
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic. "We are pleased to be presenting preclinical and clinical data on our Duchenne muscular dystrophy and myotonic dystrophy type 1 programs at this premier global muscle meeting," said James McArthur, PhD, President and CEO of PepGen. "Based on the totality o
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. "We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate thei
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law. Prior to PepGen, Ma
HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.
Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.
10-Q - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13D/A - PepGen Inc. (0001835597) (Subject)
4/A - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00
4 - PepGen Inc. (0001835597) (Issuer)
3 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived
- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches - - PGN-EDO51 was generally well-tolerated - - PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 - - Data supports the potential of PepGen's Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases - - Company to host conference call today at 8:00 a.m. ET to discuss these results - BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-sta